MedPage Today report that evidence from Australia and Canada indicate that regulation of stem cell therapy companies can help to curb the sale of unproven stem cell therapies.
In Australia, medical regulators tightened rules over the advertising and provision of autologous cell and tissue products in 2018.
In North America, Health Canada issued cease-and-desist letters to 36 clinics marketing unproven stem cell therapies in 2019.
A recently published article in Cell Stem Cell, suggests that targeted regulatory action can have meaningful effects.
